From: Implementation of medicines pricing policies in sub-Saharan Africa: systematic review
Domains | Specific medicine pricing policy | Country | Reference |
---|---|---|---|
Targeted public subsidies | Affordable Medicines Facility for malaria | Uganda, Tanzania, Kenya, Ghana, Nigeria, Niger, Madagascar | Fink, 2014 [41], Sabot 2009 [38], Smith, 2011 [37], Tougher 2014 [62], Ye 2015 [66] |
Free medicines scheme | Cameroon, Mali | ||
Equity fund | Madagascar | Honda 2013 [53] | |
Subsidy schemes | Tanzania, Uganda, Senegal | ||
Regulatory framework and direct price control | State price regulation frameworks | Angola, Botswana, Democratic Republic of Congo, Lesotho, Malawi, Mozambique, Namibia, South Africa, Swaziland, Mali, Tanzania, Zambia and Zimbabwe | |
Reference-based pricing systems | South Africa | Casar & Suleman 2019 [50], de Jager & Suleman 2019 [44], Rothberg 2004 [61], Steyn 2007 [43] | |
Single exit price (SEP) policies | South Africa | Steyn 2007 [43], Moodley & Suleman 2019a [57] and Moodley and Suleman 2019b [58], Bangalee and Suleman 2016 [45], Bangalee and Suleman 2019 [46] | |
Pharmacy and Poisons Act | Sudan | Ali and Yahia 2012 [36] | |
Reimbursement schemes | Ghana | Ashigbie 2016 [49] | |
Generic medicine pricing policies | Generic medicine pricing policies | South Africa, Mali, Kenya | Bangalee and Suleman 2016 [45], Bangalee and Suleman 2019 [46], de Jager and Suleman 2019 [44], Maïga 2010 [55], Nicolosi 2009 [59], Ongarora 2019 [60] and Wilson 2012 [65] |
Cost recovery and generics | Mali | Maïga 2003 [56] | |
Purchasing policies | Public-private partnership | South Africa, Tanzania | |
Revolving drug fund policy | Sudan, Kenya |